Omeros Doesn’t Look Like That Much Of An Opportunity – Seeking Alpha

by admin on March 14, 2013

Omeros Doesn't Look Like That Much Of An Opportunity
Seeking Alpha
Further down the list, Omeros has compounds under development that target PDE7 (largely for movement disorders like Parkinson's and restless leg syndrome) and PPAR-gamma for addictions. The company also has an investigational G protein-coupled

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: